The invention discloses a huperzine A controlled release preparation having a biphasic release behavior. The in-vivo and in-vitro biphasic release distribution of the huperzine A controlled release preparation is carried out within a predetermined time quantum, wherein a first phase is a rapid release phase, a second phase is a slow release phase, and the rapid release phase contains 5-50wt% of a drug active component. The huperzine A controlled release preparation rapidly takes effect after the preparation is taken; the preparation is continuously released within a needed physiologic period (daytime) and improves the memory, cognition and behavior functions of patients, the plasma drug concentration can be correspondingly adjusted at low-activity-level night to reduce the appearance of the drug resistance; the preparation has small excitation to the stomach and intestine, and has a good patient compliance; and the preparation is taken once every day on the basis of an increased administration dose, so a stable blood drug concentration is maintained, a constant curative effect can be realized, the incidence rate of untoward effects is reduced, the drug use is safe, and the preparation is more suitable for the long-term use of moderate and severe Alzheimer's disease patients.